Claire Liefferinckx
YOU?
Author Swipe
View article: The identification of blood-derived response eQTLs reveals complex effects of regulatory variants on inflammatory and infectious disease risk
The identification of blood-derived response eQTLs reveals complex effects of regulatory variants on inflammatory and infectious disease risk Open
Hundreds of risk loci for immune mediated inflammatory and infectious diseases have been identified by genome-wide association studies (GWAS). Yet, what causal variants and genes in risk loci underpin the observed associations remains poor…
View article: Duodenal Organoids From Metabolic Dysfunction-Associated Steatohepatitis Patients Exhibit Absorptive and Barrier Alterations
Duodenal Organoids From Metabolic Dysfunction-Associated Steatohepatitis Patients Exhibit Absorptive and Barrier Alterations Open
View article: Duodenal organoids from metabolic dysfunction-associated steatohepatitis patients exhibit altered digestive homeostasis
Duodenal organoids from metabolic dysfunction-associated steatohepatitis patients exhibit altered digestive homeostasis Open
Background and Aims Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease that can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. Though MASH is closely tied to metabolic risk factors, the under…
View article: P418 Lipopolysaccharide-Binding Protein (LBP) in Crohn's Disease (CD) Patients: A Promising Non-Invasive Biomarker Monitoring Disease Activity
P418 Lipopolysaccharide-Binding Protein (LBP) in Crohn's Disease (CD) Patients: A Promising Non-Invasive Biomarker Monitoring Disease Activity Open
Background Current biomarkers of inflammatory bowel disease (IBD) monitoring (serum C-reactive protein (CRP) and faecal calprotectin (FC)) have limitations in terms of specificity (SP) and sensitivity (SE), especially for Crohn’s disease (…
View article: P335 Development and validation of a Belgian set of quality indicators for inflammatory bowel diseases
P335 Development and validation of a Belgian set of quality indicators for inflammatory bowel diseases Open
Background Quality indicators are standardized, evidence-based measures of health care quality, categorised as structure (to assess the care setting), process (to assess high-quality care actions by healthcare professionals) or outcome ind…
View article: Does colectomy in UC patients impact on the PSC onset?: A national registry brings new insights
Does colectomy in UC patients impact on the PSC onset?: A national registry brings new insights Open
Primary sclerosing cholangitis (PSC) is a chronic liver disease quite rare in the general population but closely related to inflammatory bowel disease (IBD) as 70%–80% of PSC patients have a concomitant IBD.1, 2 This close relationship bet…
View article: Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility
Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility Open
View article: Predictive models assessing the response to ustekinumab highlight the value of therapeutic drug monitoring in Crohn’s disease
Predictive models assessing the response to ustekinumab highlight the value of therapeutic drug monitoring in Crohn’s disease Open
View article: Crohn’s disease-related ‘gastrocnemius myalgia syndrome’ successfully treated with infliximab: A case report
Crohn’s disease-related ‘gastrocnemius myalgia syndrome’ successfully treated with infliximab: A case report Open
The GMS represent a rare CD-associated inflammatory myopathy for which anti-tumour necrosis factor-α therapy might be considered as an effective therapeutic option.
View article: Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies
Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies Open
Background and Aims Although subcutaneous formulations of infliximab CT-P13 and vedolizumab are registered for treating moderate-to-severe inflammatory bowel disease [IBD], many questions on their use remain unanswered. We set up a multi-s…
View article: P386 Predictive models for assessing the response to ustekinumab in Crohn’s disease patients
P386 Predictive models for assessing the response to ustekinumab in Crohn’s disease patients Open
Background The loss of response to biologics remains a clinical challenge for which the discovery of predictive factors is helpful. In this direction, exploiting tree-based models on top of logistic regression (LR) allows to uncover unexpe…
View article: Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study Open
Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third…
View article: Sequencing of over 100,000 individuals identifies multiple genes and rare variants associated with Crohns disease susceptibility
Sequencing of over 100,000 individuals identifies multiple genes and rare variants associated with Crohns disease susceptibility Open
Genome-wide association studies (GWAS) have identified hundreds of loci associated with Crohns disease (CD), however, as with all complex diseases, deriving pathogenic mechanisms from these non-coding GWAS discoveries has been challenging.…
View article: P280 Introduction of subcutaneous infliximab CT-P13 and vedolizumab in daily clinical practice: outstanding questions demonstrate the need for post-marketing studies
P280 Introduction of subcutaneous infliximab CT-P13 and vedolizumab in daily clinical practice: outstanding questions demonstrate the need for post-marketing studies Open
Background Although clinical trials led to the registration of subcutaneous (SC) infliximab CT-P13 (IFX) and SC vedolizumab (VDZ) for patients with Crohn’s disease (CD) and ulcerative colitis (UC), many practical aspects have not been addr…
View article: New approach to determine the healthy immune variations by combining clustering methods
New approach to determine the healthy immune variations by combining clustering methods Open
View article: Collecting New Peak and Intermediate Infliximab Levels to Predict Remission in Inflammatory Bowel Diseases
Collecting New Peak and Intermediate Infliximab Levels to Predict Remission in Inflammatory Bowel Diseases Open
Background The loss of response to infliximab is a challenge for clinicians in the management of inflammatory bowel disease (IBD). Mounting evidence suggests that therapeutic drug monitoring at induction may predict remission during mainte…
View article: Switching biologics used in inflammatory bowel diseases: how to deal with in practice?
Switching biologics used in inflammatory bowel diseases: how to deal with in practice? Open
View article: Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy
Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy Open
Summary Background Ustekinumab is effective in Crohn's disease. However, a substantial proportion of patients will not respond or lose response to ustekinumab. The current evidence to support the effectiveness of dose‐optimisation for uste…
View article: New insights in acetaminophen toxicity: HMGB1 contributes by itself to amplify hepatocyte necrosis in vitro through the TLR4-TRIF-RIPK3 axis
New insights in acetaminophen toxicity: HMGB1 contributes by itself to amplify hepatocyte necrosis in vitro through the TLR4-TRIF-RIPK3 axis Open
View article: DOP38 Prevalence of fatigue in a severe inflammatory bowel disease cohort highly exposed to biologics
DOP38 Prevalence of fatigue in a severe inflammatory bowel disease cohort highly exposed to biologics Open
Background In addition to physical and psychological factors, systemic inflammation, anaemia and/or malnutrition contribute to fatigue in Crohn’s disease (CD) and ulcerative colitis (UC). Despite recent advances in the management of the di…
View article: P115 Real-world experience of peri-operative treatments on surgical complications after Ileo-caecal resection in Crohn’s disease
P115 Real-world experience of peri-operative treatments on surgical complications after Ileo-caecal resection in Crohn’s disease Open
Background The current recommendations remain vague as to whether biologics are safe or deleterious when surgery is contemplated in patients with Crohn’s disease (CD). Conflicting data do not enable to adopt a definitive position on the ti…
View article: P346 Single-centre experience of ustekinumab: Therapeutic drug monitoring in Crohn’s disease patients
P346 Single-centre experience of ustekinumab: Therapeutic drug monitoring in Crohn’s disease patients Open
Background Therapeutic drug monitoring (TDM) is a diagnostic tool in the monitoring of anti-TNF therapies. Yet, the benefit for TDM of new biologics such as ustekinumab (USK) is still controversial in real-world experiences. Methods This m…
View article: DOP74 Effectiveness of dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous ustekinumab maintenance therapy: A multicentre international cohort study
DOP74 Effectiveness of dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous ustekinumab maintenance therapy: A multicentre international cohort study Open
Background Ustekinumab (UST) is an effective agent for induction and maintenance of response and remission in Crohn’s disease (CD). In addition to randomised controlled trials, an abundance of real-world evidence is available as well, sugg…
View article: P362 Prospective study of phArmaCokinetics of InFliximab during induction in patients with Crohn’s disease and ulcerative colitis (PACIFIC)
P362 Prospective study of phArmaCokinetics of InFliximab during induction in patients with Crohn’s disease and ulcerative colitis (PACIFIC) Open
Background Loss of response (LOR) to infliximab (IFX) remains a challenge in routine management of IBD patients. We evaluated IFX high-resolution pharmacokinetics (PK) during induction with intermediate and peak PK levels. Methods This is …
View article: Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn’s Disease Who Failed Biologic Therapies: A National Cohort Study
Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn’s Disease Who Failed Biologic Therapies: A National Cohort Study Open
Background Ustekinumab [UST] was recently approved in Europe for the treatment of moderate to severe Crohn’s disease [CD]. Long-term real-world data are currently scarce for CD patients previously exposed to several biologics. Methods This…
View article: Variability of Faecal Calprotectin in Inflammatory Bowel Disease Patients: An Observational Case-control Study
Variability of Faecal Calprotectin in Inflammatory Bowel Disease Patients: An Observational Case-control Study Open
Background and Aims Several factors have been reported to affect faecal calprotectin [FC] values, and significant variation in FC concentrations has been observed in inflammatory bowel disease [IBD] patients. We aimed to evaluate FC variab…
View article: Impact of first‐line infliximab on the pharmacokinetics of second‐line vedolizumab in inflammatory bowel diseases
Impact of first‐line infliximab on the pharmacokinetics of second‐line vedolizumab in inflammatory bowel diseases Open
Background Very little is known about the impact of the wash‐out period on the pharmacokinetics of a second‐line biologic. Objective The objective of this article is to explore the impact of two different wash‐out periods on the pharmacoki…
View article: Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance
Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance Open
Background Vedolizumab (VDZ) is effective as an induction and maintenance treatment for Crohn’s disease and ulcerative colitis, but, as observed with antitumour necrosis factor-α (anti-TNFα) agents, some patients are nonetheless experienci…
View article: Viewpoint: Toward the Genetic Architecture of Disease Severity in Inflammatory Bowel Diseases
Viewpoint: Toward the Genetic Architecture of Disease Severity in Inflammatory Bowel Diseases Open
Inflammatory bowel disease (IBD) is characterized by uneven disease courses with various clinical outcomes. A few prognostic markers of disease severity may help stratify patients and identify those who will benefit the most from early agg…
View article: P753 Vedolizumab trough levels during induction in IBD patients: A longitudinal observational retrospective study
P753 Vedolizumab trough levels during induction in IBD patients: A longitudinal observational retrospective study Open
Vedolizumab (VDZ) is effective for the treatment of ulcerative colitis (UC) or Crohn’s disease (CD). Few real-world experience data are available on the relevance of measuring trough levels (TLs) early on to predict loss of response in pat…